Pfizer says its COVID-19 vaccine is 95% effective in final clinical trial results analysisTechCrunch • 11/18/20
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy EndpointsBusiness Wire • 11/18/20
The Motley Fool Sits Down With A Doctor About Pfizer's Coronavirus Vaccine NewsThe Motley Fool • 11/18/20
Pfizer says final data analysis shows Covid vaccine is 95% effective – plans to submit to FDA in 'days'CNBC • 11/18/20
Better Coronavirus Vaccine: Moderna's mRNA-1273 or Pfizer and BioNTech's BNT162b2?The Motley Fool • 11/17/20
BioNTech, Pfizer stocks fall after upbeat news on Moderna's COVID-19 vaccine candidateMarket Watch • 11/16/20
The creator of the Pfizer-BioNTech vaccine says life could return to normal by next winterCNBC • 11/16/20
Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPOSeeking Alpha • 11/15/20
Coronavirus Vaccine Stocks: Challenges With Manufacturing, Distribution, And the Cold ChainThe Motley Fool • 11/14/20
The Tell: Pfizer vaccine news sparks $44.5 billion flood into the stock market—its biggest weekly inflow ever, says BofAMarket Watch • 11/13/20
BioNTech and Pfizer's COVID-19 vaccine is surprisingly effective, though experts question what effectiveness will look like in the real worldMarket Watch • 11/13/20